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Introduction. Anemia is a frequent problem in hospitalized geriatric patients, and the anemia of chronic disease (ACD) and iron
deﬁciency anemia (IDA) are the 2 most prevalent causes. The aim of the study was to assess the possible role of serum hepcidin in
the diﬀerential diagnosis between ACD and IDA. Methods. We investigated serum hepcidin, iron status, anemia, and C-reactive
protein in 39 consecutive geriatric patients with ACD and IDA. Serum hepcidin levels were determined using a commercial ELISA
kit (DRG Instruments, Marburg, Germany). We also measured hepcidin in 26 healthy controls. Results. The serum hepcidin levels
werenotsigniﬁcantlyhigherinthe28patientswithACDascomparedtothe11patientswithIDA.Conclusions.Theserumhepcidin
levels measured using the commercial ELISA kit (DRG) do not appear to increase in older patients with ACD. It should be noted
that an assay-speciﬁc problem could explain our results.
1.Introduction
The anemia of chronic disease (ACD) and iron deﬁciency
anemia (IDA) are the 2 most prevalent causes of anemia in
hospitalized geriatric patients [1]. An inﬂammatory process
plays a central role in the pathogenesis of the ACD with low
serum iron and normal or increased iron stores, while the
absence of iron stores is the hallmark of the IDA [2]. How-
ever, the diﬀerential diagnosis between these two causes of
anemia is often diﬃcult in clinical practice. The diagnosis is
even a greater challenge in case of the combination of ACD
and IDA in the same patient. Serum ferritin has been the
most commonly used single laboratory parameter to discri-
minate between ACD and IDA [2]. However, there is no
agreementonthelowerreferencevalue,anditslevelincreases
in response to an underlying inﬂammatory process. The cli-
nical signiﬁcance of other laboratory parameters such as the
serum transferrin receptor remains unclear and is not widely
used [3]. A bone marrow investigation has been considered
by some investigators as the gold standard to assess the iron
status, but others have found that this investigation is not
always diagnostic for iron deﬁciency [4]. Research on the
pathogenesis of ACD has recently focused on the role of hep-
cidin, a 25 amino acid peptide synthesized in the liver and
triggered by inﬂammatory stimulators such as interleukin-6.
This peptide appears to be a key regulator of iron homeosta-
sis [5].
2. Patients andMethods
Our study group comprises 39 consecutive elderly patients
(mean age 83.4y, 32 females and 7 males) with ACD and
IDA and admitted to the acute geriatric ward of our hos-
pital. Anemia was deﬁned as a hemoglobin concentration
<11.5g/dL for men and women. In order to assess the clini-
cal signiﬁcance of the hepcidin analysis, we chose to deﬁne
IDAandACDaccordingtostringentbutnoninvasivecriteria.
Eleven patients were considered to have IDA deﬁned as a
serum ferritin level ≤20µg/L. Twenty-eight patients were
consideredtohaveACD,andtheyfulﬁlledallofthefollowing
criteria: serum ferritin >100µg/L, serum transferrin satu-
ration <16%, C-reactive protein (CRP) >10mg/L, and the2 ISRN Hematology
presence of an acute or chronic inﬂammatory process (acute
pneumonia 11, urinary tract infection 7, cancer 6, chronic
osteomyelitis 1, decubitus ulcer 2, giant cell arthritis 1). Pa-
tients with a serum creatinine >2mg/dL, another established
cause for the anemia, or treated with iron or blood transfu-
sion during the last 2 months were also excluded. Peripheral
bloodcounts,CRP,serumtransferrinsaturation,serumiron,
serum ferritin, and serum creatinine were determined in
morning specimens collected after an overnight fast accord-
ing to routine laboratory analyses. For the measurement of
hepcidin, a serum aliquot was frozen immediately at −70◦C.
Serum levels of hepcidin were determined in batch using a
commercial ELISA kit (DRG Instruments, GmbH, Marburg,
Germany) according to the manufacturer’s protocol. The
within and between assay coeﬃcient of variation is <4.9%
and <11.5%, respectively. The dynamic range of the assay is
between 0.9 to 140ng/mL. The 5 to 95% range in apparently
normal healthy adults is 13.3 to 54.4ng/mL according to the
manufacturer. We also studied a group of 26 healthy volun-
teers (mean age 46y, 4 men and 22 females). These controls
were not anaemic (hemoglobin concentration >13g/dL for
men and >12g/dL for women), had a ferritin level >16µg/L
(women) and >30µg/L (men) and a CRP <5mg/L.
Statistical Analysis: Means were compared by student’s
t-test for the evaluation of the baseline characteristics, and
the 1-way analysis of variance was used for the statistical cal-
culations between the various groups (SPSS 19). Log trans-
formed data were used for serum ferritin, transferrin satu-
ration, CRP, and serum hepcidin levels. This study was ap-
proved by the ethical committee of the University Hospitals
Leuven.
3. Results
The characteristics of the 11 patients with IDA and the 28
patients with ACD are shown in Table 1.I ti sr e m a r k a b l e
that the serum hepcidin levels were comparable between the
patientswithIDAandACD.Thehighesthepcidinlevelinthe
IDA group was 49.9ng/mL, and only 3 out of the 28 patients
in the ACD group had a higher level (see Figure 1). The CRP
level was <5mg/Lin8and>10mg/L in 3 patients with IDA.
When the total study group was arbitrarily subdivided in
those with (CRP level >20mg/L) and without (CRP level
≤20mg/L)inﬂammationaswealsodidinourpreviousstudy
[3], the geometric mean for the serum hepcidin level in the
25 patients with a CRP level >20mg/L was 35.2ng/mL (95%
range 17 to 72ng/mL) and 32.8ng/mL (95% range 12 to
90ng/mL) in the 13 patients with a CRP level <20mg/L (P =
0.61).
The geometric mean for the hepcidin concentration in
the 26 healthy volunteers was 28.1ng/mL (5 to 95% range
20.5ng/mL to 66ng/mL) which was not statistically diﬀer-
ent compared to the hepcidin levels in patients with ACD
and IDA (ANOVA, P = 0.53).
4. Discussion
We found comparable serum hepcidin levels in patients with
ACD and IDA. The 5 to 95% referenceinterval in our control
Table 1: Characteristics of the patients with iron deﬁciency anemia
and anemia of chronic disease. M: male; F: female; IDA: iron deﬁci-
ency anemia; ACD: anemia of chronic disease; MCV: mean corpus-
cular volume; CRP: C-reactive protein.
IDA ACD P-value
Number (M/F) 11 (2/9) 28 (5/23)
Age (years), mean (SD) 81 (7.3) 84 (5.8) 0.2
Hemoglobin (g/dL),
mean (SD) 8.9 (2.1) 10.1 (0.8) 0.1
MCV (fL), mean (SD) 80 (6) 91 (3.4) <0.001
Ferritin (µg/L),
geometric mean (95%
range)
13.3 (5.6–32) 250 (88–715) <0.001
Transferrin saturation
(%), geometric mean
(95% range)
5.9 (2–17) 10.1 (4.6–22) <0.001
CRP (mg/L), geometric
mean (95% range) 4 (0.4–52) 49 (4.6–515) <0.001
Hepcidin (ng/mL),
geometric mean (95%
range)
32.4
(19.5–54)
35.3
(13.7–90) 0.58
population was comparable to the data delivered by the
manufacturer. It is noteworthy that none of our control sub-
jects had clinical or laboratory signs of inﬂammation or iron
deﬁciency.
Our results are, however, not in accordance with four
recent studies [6–9]. Ganz et al. found that the serum hep-
cidin levels were undetectable in 18 of the 19 patients with
iron deﬁciency (serum ferritin <10µg/L) but signiﬁcantly
elevated in patients with inﬂammation deﬁned as a CRP
>10mg/L. There is no information regarding the ferritin
concentration in patients with inﬂammation in this study
[6]. In another study, Theurl et al. showed that patients with
ACD had signiﬁcantly higher serum hepcidin levels than
patients with IDA, ACD/IDA, and controls [8]. Due to the
deﬁnition of subpopulations in the study by Theurl et al.,
ferritinwasalsosigniﬁcantlydiﬀerentbetweenthesubgroups
of ACD with and without iron deﬁciency [8]. Thomas et
al. studied a 155 anaemic patients with latent iron deﬁci-
ency and reported that serum hepcidin can diﬀerentiate pa-
tients with IDA from ACD and ACD/IDA. Serum hepcidin
correlated with ferritin and ferritin index [9]. On the other
hand, urinary hepcidin levels were not correlated with pro-
inﬂammatory markers in a large sample of an older general
population [7].
There are several limitations to our study. Our study
population is by its nature a heterogeneous group of vulne-
rable geriatric patients. Aging is associated with increased in-
ﬂammation and a mild rise in inﬂammatory markers such as
IL-6, but additional laboratory analyses were not performed.
A higher CRP level is common in hospitalized older patients
with IDA [3], and 3 out of the 11 patients with IDA had a
CRP >10mg/L. We are also aware that the number of pa-
tients is limited, but we doubt whether a larger group could
signiﬁcantly alter our results. Although there are no standard
criteria for the diagnosis of ACD and IDA, we chose to deﬁneISRN Hematology 3
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Figure 1: Serum hepcidin levels in 26 healthy controls (cont), 28 patients with anemia of chronic disease (ACD) and 11 patients with iron
deﬁciency anemia (IDA).
our study groups according to well-established laboratory
criteria. Finally, several mass spectrometry and immuno-
chemical methods have been developed for hepcidin quan-
tiﬁcation in serum and urine. Currently, there is no reference
method for hepcidin measurements. A generally accepted
reference interval is not yet available at this moment, nor a
validatedcutoﬀforthediagnosisofIDAorACD.Inthestudy
by Kroot et al., several quantitative methods were compared
[10].Theanalyticalvariationofthemethodswascomparable
andwaslowforallmethods[10].However,thehepcidincon-
centrations in urine and serum diﬀered considerably bet-
ween all methods. These diﬀerences are suggested to be
caused by (i) the use of diﬀerent calibrators, (ii) possible
hepcidin aggregation in the sample or the standard solution,
(iii) measuring only free, only bound, or both fractions of
hepcidin, or (iv) by interference of hepcidin isoforms [10].
The commercial DRG ELISA assay used in this study was not
included in the comparison study of Kroot et al. [10].
In conclusion, this is the ﬁrst study that investigates the
possible role of serum hepcidin for the diagnosis of diﬀerent
types of anemia in a geriatric hospitalized population using a
commercially available DRG ELISA kit. According to other
recent studies, we would expect higher hepcidin levels in
ACD and lower levels in IDA patients as compared to our
control group. The reason for this is not clear, although an
assay-related problem that could explain these inadequate
resultsispossible.However,atthismomentitisprematureto
draw ﬁrm conclusions, and further investigation is needed.
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